SyncoZymes Bio-pharma
SyncoZymes Bio-pharma, headquartered in China, is a leading player in the biopharmaceutical industry, specialising in innovative enzyme solutions and bioprocessing technologies. Founded in 2010, the company has rapidly expanded its operational footprint across Asia and Europe, establishing itself as a trusted partner in the development of cutting-edge therapeutics. With a focus on enzyme production and biocatalysis, SyncoZymes offers unique products that enhance the efficiency and sustainability of pharmaceutical manufacturing processes. Their commitment to research and development has led to significant advancements in enzyme applications, positioning them as a frontrunner in the market. Recognised for their quality and innovation, SyncoZymes Bio-pharma continues to achieve notable milestones, contributing to the evolution of the biopharmaceutical landscape while addressing the growing demand for environmentally friendly production methods.
DitchCarbon Score
How does SyncoZymes Bio-pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SyncoZymes Bio-pharma's score of 0 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SyncoZymes Bio-pharma's reported carbon emissions
SyncoZymes Bio-pharma, headquartered in CN, currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is essential to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and climate commitments. This includes initiatives aimed at reducing greenhouse gas emissions across all scopes—Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). As the industry evolves, it is anticipated that SyncoZymes Bio-pharma may adopt similar strategies to enhance their environmental performance and contribute to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SyncoZymes Bio-pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
